How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill.

Read it at Medical Xpress ↗

Join the argument

House rules →

Comments load as you scroll.

← Front page

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages — SignalPop